UPDATE 1-Vertex to sell rights to hepatitis C drug payments | Markets | Markets News | Reuters

"Vertex Pharmaceuticals Inc (VRTX.O) said on Friday it planned to sell rights to future milestone payments tied to progress in Europe for its high-profile experimental hepatitis C drug."